Research Information System
UHOD - Uluslararasi Hematoloji-Onkoloji Dergisi, vol.35, no.1, pp.12-16, 2025 (SCI-Expanded)
Despite the poor prognosis of KRAS mutant metastatic colorectal cancer (mCRC), some KRAS mutant mCRC patients have a better prognosis and survival rate than other RAS mutant mCRC patients. We aimed to determine the impact of the clinicopathological features and the type of mutational status on the survival rate of patients diagnosed with KRAS mutant mCRC. The Kaplan–Meier method and the log-rank test were used to analyse overall survival (OS). Cox regression analyses were used to determine the association between OS and other explanatory variables. We demonstrated that left-sided mCRC had better OS rates compared with right-sided mCRC (p= 0.007). De novo metastatic disease had better OS rates compared with the absence of de novo metastatic disease (p=0.001). Additionally, absence of de novo metastatic disease and right sided tumors were shown to be poor prognostic markers for OS in multivariate analysis (p< 0.001 and p= 0.001, respectively). Right-sided colon tumors and the absence of de novo metastatic disease are poor prognostic markers for OS.